The goal of the project was to set up a Nordic consortium that would plan a new approach in studying brain disease therapies and mechanisms. The indication areas was restricted to four major diseases namely stroke, Alzheimer’s disease, Parkinson’s disease, and brain trauma.
For the forming of the consortium, the project leader CEO Juha Yrjänheikki, from Cerebricon Ltd, contacted and met tens of companies, universities, and their lead scientists/business development people.
The main focus was on Finland, Sweden, Norway, and Denmark, but also Estonia was included. After the first interviews and meetings, a consortium consisting of Cerebricon Ltd, University of Kuopio, Karolinska Institute Stockholm, Neuromics Inc Stockholm was formed.
The goal was to set up a stroke and/or CNS pain program, in which Cerebricon and University of Kuopio would test certain antisense ncleotide therapies developed by Neuromics and Karolinska Institute. However, this initial consortium was terminated due to the financial problems of Neuromics Sweden.